Announced Fri, 18 Sept, 2026 · 18:21 IST
Laurus Labs Q1 FY27 investor presentation, revenue up 29 percent YoY
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.5%1-day move
₹1974.00
prior close
₹1966.60
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+0.8+0.8+1.1+1.5+2.9+2.6+1.7+1.9+0.3————
Up moveDown movePending
AI summary
Q1 FY27 revenue grew 29 percent to Rs 2,026 Cr driven by CDMO and Affordable Medicines. EBITDA rose 66 percent to Rs 644 Cr with margins at 31.8 percent, up 700 bps. Net profit jumped 126 percent to Rs 368 Cr. Company guides above 30 percent EBITDA margins from FY27 onwards. CAPEX of over Rs 3,000 Cr planned across FY27 and FY28, with 85 percent towards growth projects.
Likely market impact
Strong quarter, margin guidance above 30 percent, and rising CDMO mix signal improving profitability and sustained growth outlook.